Evidence map›Paper›PMID 27343465›Full record

ArticleBiomaterials2016

Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma.

Rong Liu, Aaron H Colby, Denis Gilmore, Morgan Schulz, Jialiu Zeng, Robert F Padera, Orian Shirihai, Mark W Grinstaff, Yolonda L Colson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. Article
  5. Article
  6. Pilot-scale production of expansile nanoparticles: Practical methods for clinical scale-up.Journal of controlled release : official journal of the Controlled Release Society · 2021
    Article
  7. Tumor-mesoporous silica nanoparticle interactions following intraperitoneal delivery for targeting peritoneal metastasis.Journal of controlled release : official journal of the Controlled Release Society · 2020
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Rong LiuDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Aaron H ColbyDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Departments of Biomedical Engineering and Chemistry, Boston University, Boston, MA, USA.
Denis GilmoreDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Morgan SchulzDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jialiu ZengDepartments of Biomedical Engineering and Chemistry, Boston University, Boston, MA, USA.
Robert F PaderaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Orian ShirihaiDepartment of Medicine, Obesity and Nutrition Section, Evans Biomedical Research Center, Boston University School of Medicine, Boston, MA, USA; Department of Clinical Biochemistry, School of Medicine, Ben Gurion University, Beer-Sheva, Israel.
Mark W GrinstaffDepartments of Biomedical Engineering and Chemistry, Boston University, Boston, MA, USA. Electronic address: mgrin@bu.edu.
Yolonda L ColsonDepartment of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: ycolson@partners.org.
Harvard University · USBoston University · USBrigham and Women's Hospital · US

Funding

ADVANCED TRAINING IN SURGICAL ONCOLOGYT32CA009535 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BUENO, RAPHAEL · 1985 to 2015
$3.5M
Boston University Cross-Disciplinary Training in Nanotechnology for CancerR25CA153955 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI FALLER, DOUGLAS V, GOLDBERG, BENNETT B · 2010 to 2014
$2.1M
Large Scale Synthesis and Biodistribution of Expansile NanoparticlesR43CA189215 · NCI · IONIC PHARMACEUTICALS · PI COLBY, AARON HENRY · 2014 to 2014
$225k
NCI NIH HHS R25 CA153955NCI NIH HHS R43 CA189215NCI NIH HHS T32 CA009535
6 · The paper itself

Abstract

The treatment outcomes for malignant peritoneal mesothelioma are poor and associated with high co-morbidities due to suboptimal drug delivery. Thus, there is an unmet need for new approaches that concentrate drug at the tumor for a prolonged period of time yielding enhanced antitumor efficacy and improved metrics of treatment success. A paclitaxel-loaded pH-responsive expansile nanoparticle (PTX-eNP) system is described that addresses two unique challenges to improve the outcomes for peritoneal mesothelioma. First, following intraperitoneal administration, eNPs rapidly and specifically localize to tumors. The rate of eNP uptake by tumors is an order of magnitude faster than the rate of uptake in non-malignant cells; and, subsequent accumulation in autophagosomes and disruption of autophagosomal trafficking leads to prolonged intracellular retention of eNPs. The net effect of these combined mechanisms manifests as rapid localization to intraperitoneal tumors within 4 h of injection and persistent intratumoral retention for >14 days. Second, the high tumor-specificity of PTX-eNPs leads to delivery of greater than 100 times higher concentrations of drug in tumors compared to PTX alone and this is maintained for at least seven days following administration. As a result, overall survival of animals with established mesothelioma more than doubled when animals were treated with multiple doses of PTX-eNPs compared to equivalent dosing with PTX or non-responsive PTX-loaded nanoparticles.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicAutophagosomesCell Line, TumorDrug CarriersDrug Delivery SystemsFemaleHumansMesotheliomaMice, NudeNanoparticlesPaclitaxelPeritoneal NeoplasmsPeritoneumAntineoplastic Agents, PhytogenicDrug CarriersPaclitaxelAutophagosomeDrug deliveryMesotheliomaNanoparticlePaclitaxelTumor localization

Identifiers

PMID27343465
PMCPMC4948582
OpenAlexW2462808684

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.